Actinic Keratosis
Conditions
Brief summary
To compare the safety and efficacy profiles of AM001 Cream, 7.5% and its vehicle cream in the treatment of Actinic Keratosis (AK) Lesions
Detailed description
A Phase 2, Single-Center, Randomized, Double- Blind, Parallel-Group, Vehicle-Controlled Study Evaluating the Efficacy and Safety of AM001 Cream in the Treatment of Actinic Keratosis (AK) Lesions
Interventions
Active Cream
DRUGVehicle Cream
Placeo
Sponsors
AmDerma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Subject must provide written informed consent. 2. Subject must be male or non-pregnant females of any race, and any skin type aged 18 to 80 years both inclusive. 3. Subject has 4 to 8 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions, each at least 4 mm in diameter within a 25cm² contiguous treatment area on the face or the balding scalp. 4. Subject is willing to avoid exposure to sunlight, use of tanning booths, sunlamps, or nonprescription UV (ultra-violate) light sources during the study period.ooths, sunlamps, or nonprescription UV (ultra-violate) light sources during the study period. 5. If female subject of childbearing potential, the subject must have a negative urine pregnancy test at Visit 1/ Screening and must have been using an acceptable form of birth control for at least 2 months prior to Visit 1/ Screening and is willing to continue birth control during the study. 6. Subject must be willing and able to understand and comply with the requirements of the study, apply the assigned investigational product as instructed, return for the required study visits, comply with therapy prohibitions. 7. Subject must be in good health, as confirmed by medical history and physical exam, and free from any clinically significant disease/condition, other than actinic keratosis, that might interfere with the study evaluations.
Exclusion criteria
1. Subject has very thick and/or hyperkeratotic actinic keratosis AK lesions in the treatment area. 2. Subject has used topical treatment of actinic keratosis in the treatment area with 5-fluorouracil, imiquimod, diclofenac, corticosteroids or retinoids within 1 month prior to Visit 2/Baseline or during the study. 3. Subject has used treatment with PDT (photodynamic therapy) or physical therapies (e. g. cryotherapy, curettage or surgical treatment) in the treatment area within 1 month prior to Visit 2/Baseline or during the study. 4. Subject has used chemical peel, dermabrasion, laser abrasion, PUVA (prosalen plus ultraviolet A) therapy or UVB therapy within 6 months prior to Visit 2/Baseline or during the study. 5. Subject has used immunomodulators or immunosuppressive therapies, interferon, oral corticosteroids, oral retinoids or cytotoxic drugs within 1 month prior to Visit 2/Baseline or during the study. 6. Subject has untreated basal cell carcinoma, squamous cell carcinoma or melanoma in the treatment area. 7. Subject has suntan or tattoos that may interfere with the assessments in the treatment area. 8. Subject has dermatological diseases in the treatment area that may interfere with the assessments, e.g. acute skin inflammation, atopic dermatitis, eczema, rosacea, psoriasis, seborrheic dermatitis, peri-oral dermatitis or hyperpigmentation. 9. Subject who consumes excessive amount of alcohol, abuse or have any condition that in the investigator's opinion would compromise compliance, with this protocol. 10. Subject has history of malignancy not in remission for at least 5 years excluding basal cell carcinoma and nonperiorificial squamous cell carcinoma of the skin. 11. Female subject who is pregnant, nursing or planning a pregnancy within the study participation period 12. Subject has symptoms of a clinically significant illness that may influence the outcome of the study in the 4 weeks prior to Visit 1/Screening. 13. Subject has participated in another clinical trial involving investigational product or device in the 4 weeks prior to Visit 1/Screening. 14. Subject has known allergic reactions to components of the investigational product.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete clearance of all lesions | 8 weeks post treatment | (100 % of all AK lesions cleared) 8 weeks post treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete clearance of all baseline lesions weeks of treatment | 16 weeks | (100% of baseline AK lesions cleared) after 16 weeks of treatment |
| Complete clearance of all lesions | 12 weeks | (100% of baseline AK lesions cleared) after 12 weeks of treatment |
Countries
United States
Outcome results
None listed